BIND Therapeutics and Pfizer have extended the terms of their global collaboration to create Accurins that enhance the therapeutic potential of two cancer drugs in the latter’s pipeline. 

Under the original 2013 agreement, Pfizer can exercise its option to acquire the exclusive license for the first program by September 2015, but the timeframe for the second program has been expanded through March 2016.

Accurins are targeted and programmable therapeutics churned out through BIND’s nanoengineering platform. They selectively accumulate in diseased tissues and cells to deliver therapeutic payload at the site of the tumour, and thereby also reduce exposure to healthy tissues.

BIND’s technology has already caught the eyes of pharma heavyweights such Roche, AstraZeneca and Amgen, which are all collaborating on the development of Accurins based on their own investigational medicines.